Patents by Inventor Steven K. Wetter

Steven K. Wetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8367825
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xu Guozhang, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Kamachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 8299082
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Substituted Pyrimidinyl Oxime Kinase Inhibitors
    Publication number: 20120157412
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 21, 2012
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8153791
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES
    Publication number: 20110077249
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Application
    Filed: September 29, 2010
    Publication date: March 31, 2011
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 7888380
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: February 15, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
    Patent number: 7605154
    Abstract: The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: October 20, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Eva Binnun, Peter J. Connolly, Sigmond G. Johnson, Ronghui Lin, Steven A. Middleton, Sandra J. Moreno-Mazza, Niranjan B. Pandey, Steven K. Wetter
  • SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS
    Publication number: 20090111810
    Abstract: The present invention is directed to substituted pyrimidine-5-carboxamide and 5-carboxylic ester compounds of Formula (I): and forms thereof wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein and their synthesis and use as kinase inhibitors for treating a chronic or acute protein kinase mediated disease.
    Type: Application
    Filed: October 16, 2008
    Publication date: April 30, 2009
    Inventors: Peter J. Connolly, Terry V. Hughes, Steven K. Wetter
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 7384979
    Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: June 10, 2008
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, William V. Murray, Steven K. Wetter, Sigmond Johnson, Victor T. Bandurco, Jacqueline Bussolari
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 7317031
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: January 8, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Shenlin Huang, Steven K. Wetter, Peter J. Connolly, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 7153869
    Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: December 26, 2006
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Amino substituted pyridinyl methanone compounds useful in treating kinase disorders
    Patent number: 7109220
    Abstract: The present invention provides amino substituted pyridinyl methanone compounds; pharmaceutical compositions comprising the compounds and methods of synthesis thereof. The compounds, which are cyclin dependent kinase (CDK) inhibitors, can be used to treat or ameliorate CDK mediated disorders. The invention thus also provides the therapeutic or prophylactic use of the compounds and/or pharmaceutical compositions to treat such disorders.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: September 19, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ronghui Lin, Steven K. Wetter, Yanhua Lu, Peter J. Connolly, Stuart Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 6924302
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: August 2, 2005
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted amino acids as erythropoietin mimetics
    Publication number: 20040248815
    Abstract: This invention relates to a series of substitituted amino acids of Formula I 1
    Type: Application
    Filed: March 12, 2004
    Publication date: December 9, 2004
    Applicant: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 6750369
    Abstract: This invention relates to a series of substituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: June 15, 2004
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Substituted triazole diamine derivatives as kinase inhibitors
    Publication number: 20040077699
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: December 21, 2001
    Publication date: April 22, 2004
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steve A. Middleton
  • Substituted amino acids as erythropoietin mimetics
    Publication number: 20020016350
    Abstract: This invention relates to a series of substitituted amino acids of Formula I 1
    Type: Application
    Filed: August 10, 2001
    Publication date: February 7, 2002
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 6310078
    Abstract: This invention relates to a series of substituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: October 30, 2001
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray